Iwao Ojima, Distinguished Professor
Director, Institute of Chemical Biology and Drug Discovery
B.S., 1968, The University of Tokyo
M.S., 1970, The University of Tokyo
Ph.D. 1973, The University of Tokyo
Phone: (631) 632-7890
Fax: (631) 632-792
Email: iojima@notes.cc.sunysb.edu
Publications
Appointments:
1973-1983 Senior Research Fellow and Group Leader, Sagami Institute of Chemical Research
1983 Associate Professor, Department of Chemistry, State University of New York at Stony Brook
1984 Professor, Department of Chemistry, State University of New York at Stony Brook
1989 Professeur invité, Université Claude Bernard Lyon I, Lyon, France
1991 Leading Professor, State University of New York at Stony Brook
1995 University Distinguished Professor, State University of New York
1996 Visiting Professor, The University of Tokyo, Tokyo, Japan
1997 Visiting Professor, The Scripps Research Institute, La Jolla, CA
1997 Professeur invité, Université de Paris XI, BIOCIS, Châtenay-Malabry, France
1997-2003 Chairman, Department of Chemistry, State University of New York at Stony Brook
2003-present, Director, Institute of Chemical Biology and Drug Discovery, Stony Brook.
Award and Honors:
The 25th National Young Investigator Award ("Shimpo Sho"), The Chemical Society of Japan, 1976.
Arthur C. Cope Scholar Award, the American Chemical Society, 1994.
The 51st Chemical Society of Japan Award (“Nihon Kagaku Kai Sho”) for distinguished achievements, The Chemical Society of Japan, 1999.
Emanuel B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the American Chemical Society, 2001.
Outstanding Inventor Award, The Research Foundation of the State University of New York, 2002.
NYSTAR Faculty Development Award, New York State Office of Science, Technology & Academic Research, 2002.
Fellow, John Simon Guggenheim Memorial Foundation, 1995.
Fellow, American Association for the Advancement of Science, 1997.
Fellow, New York Academy of Sciences, 2000.
Inductee, American Chemical Society, Medicinal Chemistry Hall of Fame, 2006.
Fellow, American Chemical Society, “ACS Fellow”, 2010
William and Florence Catacosinos Professor in Cancer Research, Stony Brook Foundation, 1994.
Leading Professorship, State University of New York at Stony Brook, 1991
Distinguished Professorship, State University of New York, 1995
He was invited by the Royal Swedish Academy of Sciences to serve as a nominator for the Nobel prize in chemistry for the years 1990, 1996, 2002.
Eli Lilly Lecturer, University of Kansas-Lawrence, 1990.
National Science Council Lecturer, Taiwan, 1990.
J. Clarence Karcher Lecturer, The University of Oklahoma, 1992.
George Lesher Lecturer, Rensselaer Polytechnic Institute, 1995.
Boehringer-Ingelheim Distinguished Lecturer, Colorado State University, 1997.
Weissberger-Williams Lecturer, Eastman Kodak Co., 1997.
Dr. H. Martin Friedman University Lecturer, Rutgers, State University of New Jersey, 2001.
Bristol-Meyers Squibb Distinguished Lecturer, Colorado State University, 2002.
FMC Discovery Chemistry Lecturer, FMC Corporation, 2003.
J. Clarence Karcher Lecturer, The University of Oklahoma, 2003.
Guest Editor, “Drug Resistant Tuberculosis: A Challenge in Chemotherapy”, Curr. Topics Med. Chem., 2006.
Guest Editor, “Modern Molecular Approaches to Drug Discovery”, Acc. Chem. Res., 2007.
Negishi-Brown Lecturer, Purdue University, 2007.
Guest Editor, “Modern Natural Products Chemistry in Drug Discovery”, J. Med. Chem., 2007.
Ralph A. Raphael Lecturer, University of Glasgow, UK, 2008.
The Sosnovsky Distinguished Lectureship, University of Wisconsin Milwaukee, 2008.
Senior Editor, Future Medicinal Chemistry, 2008.
Henry J. Shine Lecturer, Texas Tech University, 2009
Professional Activities:
(Senior Editor)
Future Medicinal Chemistry (2008-)
(Advisory Board)
1. Editorial Advisory Board of Journal of Molecular Catalysis (1986-1995)
2. Editorial Advisory Board of Journal of Organic Chemistry (ACS) (1995-1999)
3. Editorial Advisory Board of Organometallics (ACS) (1996-1998)
4. Editorial Advisory Board of Current Topics in Medicinal Chemistry (2002-)
5. Editorial Advisory Board of Letters in Drug Design & Discovery (2003-)
6. Editorial Advisory Board of Medicinal Chemistry (2004-)
7. Editorial Advisory Board of Bull. Chem. Soc. Jpn (2005-)
8. Editorial Advisory Board of Anti-Cancer Agents in Medicinal Chemistry (2006-)
9. Basic Science Advisory Board member, Stony Brook University Cancer Center (1999-).
10. Stony Brook University Research Park Oversight Board (2007-).
(Symposia and Conferences)
1. Chairperson, The Stony Brook Symposium on Taxol and Taxotère, "New Hope for Breast Cancer Chemotherapy" Stony Brook, NY, May (1993).
2. Chairperson, Symposium on "Recent Advances in the Chemistry of Taxane and Taxoid Anticancer Agents", 207th American Chemical Society National Meeting, San Diego, CA, March (1994).
3. Chairperson, Symposium on "Fluoroamino Acids and Peptides in Medicinal Chemistry", 210th American Chemical Society National Meeting, Chicago, IL, August (1995).
4. Organizer and Chairperson, Symposium on "New Prospects in Anticancer Agents for the 21st Century" 219th American Chemical Society National Meeting, San Francisco, CA, March (2000).
5. Organizer, Ernest Guenther Award Symposium”, the 219th American Chemical Society National Meeting, San Francisco, CA, March 2000.
6. Organizer, Ernest Guenther Award Symposium, the 229th American Chemical Society National Meeting, San Diego, CA, March (2005).
7. Organizer, Symposium on “Drug Resistant Tuberculosis – Challenge in Chemotherapy”, the 229th American Chemical Society National Meeting, San Diego, CA, March (2005).
8. Organizer, ACS Award in Organometallic Chemistry Symposium, the 231st American Chemical Society National Meeting, Atlanta, GA, March (2006).
9. Organizer, “Modern Natural Products Chemistry and Drug Discovery” Symposium, the 231st American Chemical Society National Meeting, Atlanta, GA, March (2006).
10. Organizer, “Ernest Guenther Award Symposium, the 233rd American Chemical Society National Meeting, Chicago, IL, March (2007).
11. Organizer, “Modern Molecular Strategies for Tumor-Targeting Drug Dilivery”, the 234th American Chemical Society National Meeting, Boston, MA, August (2007)
(Advisory Committee, Panel Reviewer)
1. Advisory Committee Member, NIH, Medicinal Chemistry (MCHA) Study Section (1988-1992).
2. Ad Hoc Member, Triennial Oversight Committee, Chemistry Division, NSF (1992).
3. Panel Reviewer, Basic Energy Science Program, U. S. Department of Energy (1992).
4. Advisory Committee Member Reserve, NIH (1992-1995).
5. Panel Reviewer, REU Program, Chemistry Division, NSF (1992).
6. Panel Reviewer, NSF Postdoctoral Fellowship in Chemistry (1994).
7. Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1995).
8. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1995).
9. Chemistry and Related Sciences Special Emphasis Panel, NIH, Bioorganic and Natural Product Chemistry (BNP-1) Program (1996).
10. Chemistry and Related Sciences Special Emphasis Panel, NIH, SBIR and STTR Programs (1996).
11. Panel Reviewer, NSF Small Business Innovation Research (SBIR) Program (1997).
12. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (1998).
13. Special Panel Reviewer, NIH, Medicinal Chemistry (MCHA) Study Section (2001).
14. Special Panel Reviewer, NIH, Bioorganic and Natural Product Chemistry (BNP) Study Section (2002).
15. Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2002).
16. Panel Reviewer, NCI, Basic & Preclinical Subcommittee IRG (2003).
17. Panel Reviewer, NIH, Drug Discovery & Molecular Pharmacology (DMP) Study Section, Oncological Sciences IRG (2004).
18. Panel Reviewer, NCI, National Cooperative Drug Discovery Groups for Cancer (NCDDG) IRG (2004).
19. Special Emphasis Panel Reviewer, NCI, ONC-K Study Section (2005).
20. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (2005).
21. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (AIR, AED) (Feb. and July 2008)
22. Panel Reviewer, NIH, Synthetic and Biological Chemistry A (SBCA) Study Section (June 2009)
23. Special Emphasis Panel Reviewer, NIH Challenge Grant (June 2009)
24. Panel Reviewer, NIH, SBIR/STTR Cancer Drug Development Study Section (July 2009)
25. Special Emphasis Panel Reviewer, NIH, BCMB-B Study Section (September 2010)
(American Chemical Society)
1. Executive Committee Member, Division of Organic Chemistry, American Chemical Society (1998-2001).
2. Long Range Planning Committee, Division of Medicinal Chemistry, American Chemical Society (2003-2006)
Consulting:
He has served as a consultant for E. I. du Pont, Eli Lilly, Air Products & Chemicals, Mitsubishi Chem. Corp, Nippon Steel Corp. Life Science Division, Rhone-Poulenc Rorer, ImmunoGen, Inc., Taiho Pharmaceutical Co., Milliken & Co., Aventis Pharma, OSI Pharmaceuticals, Inc., INDENA, SpA, Central Glass Co., Ajinomoto Co., Inc. (current), ChemMaster International (current), Tayler Wessing LLP (current).
Memberships
He is a member of American Chemical Society, American Association for the Advancement of Science, American Association for Cancer Research, American Peptide Society, New York Academy of Sciences, Sigma Xi, The Chemical Society of Japan, and The Society of Synthetic Organic Chemistry, Japan.
Research Interest and Activities:
His research interests include drug design and discovery (anticancer agents, antibacterial agents, enzyme inhibitors), medicinal chemistry and chemical biology, catalytic asymmetric synthesis, organic synthesis by means of organometallic reagents and catalysts, homogeneous catalysis and organometallic chemistry, peptide and peptidomimetics, beta-lactam chemistry, and organofluorine chemistry (fluoroamino acids and peptides, medicinal applications). He has published more than 400 papers and reviews in leading journals and more than l50 patents and patent applications, edited 8 books, and he has given 100 Plenary and Invited Lectures in international conferences and symposia by March 2011. SciFinder list more than 750 publications to his credit. He has also given numerous invited lectures at universities, research institutes, and industries (total >470 since his move to Stony Brook in 1983).
Selected Plenary and Invited Lectures in International Meetings since 2005:
75. 17th International Symposium on Fluorine Chemistry, Shanghai, China [W.-Y. Huang, Chairman], July 24-29, 2005. “Synthetic Organofluorine Chemistry at the Biomedical Interface”.
76. ACS Symposium on “Current Frontiers of Fluoroorganic Chemistry” [V. Soloshonok; K. Mikami, Organizers], 230 American Chemical Society National Meeting, Washington, D. C., August 28 – September 1, 2005. “Organofluorine Chemistry at the Biomedical Interface”.
77. NATO Science Advanced Study Institute “New Methodologies and Techniques in Organic Chemistry: Sustainable Development in a Secure Environment”, Siena, Italy, October 14-23, 2005. “Asymmetric Catalytic Synthesis with Novel Monodentate Biphenol-Based Monodentate Phosphorus Ligands”; (2) New Cyclizations and Cycloadditions in Organic Synthesis”.
78. NATO Science Advanced Study Institute “New Methodologies and Techniques in Organic Chemistry: Sustainable Development in a Secure Environment”, Siena, Italy, October 14-23, 2005. New Cyclizations and Cycloadditions in Organic Synthesis”.
79. Sagami Chemical Research Center 40th Anniversary Symposium, Tokyo, Japan, October 28, 2005. “Synthetic Organic Chemistry at the Biomedical Interface”.
80. Pacifichem 2005 Conference, Honolulu, Hawaii, December 15-20, 2005. “Applications of biphenol-based fine-tunable monodentate phoshite and phosphoramidite ligands to catalytic asymmetric reactions”.
81. The 4th Congress of International Drug Discovery Science and Technology (IDDST-2006), Dalian, China, May 26-June 2, 2006. “Taxane-Based Tumor-Targeting Anticancer Agents”.
82. 7th All-Russian Conference, “Fluorine Chemistry”, Moscow, Russia, June 5-9, 2006. “Organofluorine Chemistry at the Biomedical Interface”.
83. The 2nd International Conference on Joint Project of Chemical Synthesis Core Research Institutions, “Development of New Synthetic Methods and Creation of Functions”, Kyoto, Japan, August 7, 2007. “Rapid Construction of Fused Heterocycles and Carbocycles by Catalytic Cyclizations and Cycloadditions”.
84. The 2nd Negishi-Brown Lectures, Purdue University, West Lafayette, IN, August 30, 2007. “Catalytic Asymmetric Transformations with Fine-Tunable Biphenol-Based Monodentate Phosphorus Ligands”.
85. New England ACS Medicinal Chemistry Symposium, Woburn, MA, September 20, 2007. “Opportunities for Translational Research in Chemical Biology and Drug Discovery”.
86. First International Conference on Drug Design and Discovery, Dubai, UAE, February 3-6, 2008. “Design, Application, and Chemical Biology of Tumor-Targeting Drug Conjugates”.
87. The Ernest Guenther Award Symposium, 235th American Chemical Society National Meeting, New Orleans, LA, April 6-9, 2008. “Taxane-based Tumor-targeting Anticancer Agents”.
88. The Award Symposium on Fluorine Chemistry, 235th American Chemical Society National Meeting, New Orleans, LA, April 6-9, 2008. “Medicinal Chemistry and Chemical Biology of Fluoro-taxoids Anticancer Agents”.
89. Swiss Chemical Society, Medicinal Chemistry Division Mini-Symposium on Drug Targeting, Basel, Switzerland, May 29, 2008. “Design, Application, and Chemical Biology of Tumor-Targeting Drug Conjugates”.
90. 6th University of Glasgow – Schering-Plough Symposium on Synthetic Chemistry, Glasgow, UK, August 28, 2008. “Synthetic Organic Chemistry at the Biomedical Interface”.
91. 6th University of Glasgow – Schering-Plough Symposium on Synthetic Chemistry, Glasgow, UK, August 29, 2008. “Rapid Construction of Fused Heterocycles and Carbocycles by Catalytic Cyclizations and Cycloadditions”.
92. 2nd World Congress on Magic Bullets, Nürnberg, Germany, October 3-5, 2008. “Taxane-Based Tumor-Targeting Anticancer Agents’.
93. International Symposium on Fluorine-Containing Peptides, Tokyo, Japan, November 4, 2008. “Synthesis of Fluorinated Amino Acids, Dipeptides, and Taxoids by Means of beta-Lactam Synthon Method”.
94. 19th American Chemical Society Winter Fluorine Conference, St. Petersburg, FL, January 11-16, 2009. “Medicinal chemistry and chemical biology of fluorine-containing taxoid anticancer agents”.
95. 19th International Symposium on Fluorine Chemistry, Jackson Hole, WY, August 23-28, 2009, “Synthesis of Fluorinated alpha-Hydroxy-beta-amino Acids by Means of beta-Lactam Synthon Method and Their Applications to Medicinal Chemistry”.
96. 1st Tishler-Omura Symposium, Tokyo, Japan, October 30, 2009. “Synthetic Organic Chemistry at the Biomedical Interface”.
97. 3rd International Symposium on Nanomedicine (ISNM-2009), Okazaki, Japan, November 4-6, 2009. “Functionalized SWNTs as Vehicles for Tumor-Targeting Drug Delivery”.
98. Perugia Fluorine Days: Organofluorine Compounds in Biomedical and Agricultural Sciences, Perugia, Italy, July 11-15, 2010. “Medicinal Chemistry and Chemical Biology of Fluorine-Containing Taxoid Anticancer Agents”.
99. 11th Eurasia Conference on Chemical Sciences (EuAsC2S-11), The Dead-Sea, Jordan, October 6-10, 2010. “Tumor-Targeting Drug Delivery of Chemotherapeutic Agents”.
100. 10th Tateshina Conference on Organic Chemistry, Tateshina, Japan, Novermber 12-14, 2010. “Chemistry and Chemical Biology of Tumor-Targeting Anticancer Agents”.
Invited Lectures Since 2005:
420. Litpold Pharmaceuticals, Inc., Shirley, NY [5/26/05, Dr. E. Hohenschuh]
421. American Biosciences, Inc. Santa Monica, CA [7/7/05, Dr. N. Desai]
422. Kitasato Institute of Life Sciences, Graduate School of Infection Control Sciences, Shirogane, Tokyo, Japan [7/19/05, Prof. S. Omura].
423. WuXi Pharma Tech., Shanghai, China [7/27/05, Dr. S. Chen].
424. Shanghai Institute of Organic Chemistry, Shanghai, China [7/29/05, Prof. L. Dai].
425. Pharmaceutical Research Institute, Ajinomoto Co., Inc., Kawasaki, Japan [Dr. M. Shoji, October 31, 2005].
Chemical Research Laboratory, Central Glass Co., Kawagoe, Japan [Dr. K. Tsutumi, Nov. 1, 2005]
426. Science and Technology Center, Mitsubishi Chemical Group, Yokohama, Japan [Dr. M. Takai, Nov. 7, 2005].
427. The University of Tokyo, Department of Applied Chemistry, Hongo, Tokyo, Japan [Prof. M. Fujita, Nov. 9, 2005].
428. Tohoku University, Institute of Multidisciplinary Research for Advanced Materials (IMRAM) [Prof. M, Sodeoka, Nov. 10, 2005].
429. Honeycomb Worldwide, Inc., Web Seminar [Ms. D. Pe, April 7, 2006].
430. Schering-Plough Research Institute, Kenilworth, NJ [Dr. S. Venkatraman, June 21, 2006].
431. Cytokinetics, Inc., South San Francisco, CA [Dr. S. Collibee, September 13, 2006].
432. Science and Technology Center, Mitsubishi Chemical Group, Yokohama, Japan [Dr. M. Takai, October 31, 2006].
433. The University of Tokyo, Graduate School of Chemistry, Hongo, Tokyo, Japan [Prof. E. Nakamura, Nov. 1, 2006]
434. Pharmaceutical Research Institute, Ajinomoto Co., Inc., Kawasaki, Japan [Dr. M. Shoji, November 6, 2006].
435. Chemical Research Laboratory, Central Glass Co., Kawagoe, Japan [Dr. Y. Takahara, Nov. 9, 2006]
436. Kitasato Institute and Kitasato University, Shirogane, Tokyo, Japan [Nov. 10, 2006, Prof. S. Omura]
437. Sepracor Pharmaceuticals, Inc., Marlborogh, MA [Sept. 21, 2007, Dr. L. Shao]
438. University of Iowa, College of Pharmacy, Division of Medicinal & Natural Products Chemistry, Iowa City, IA [October 2, 2007, Prof. Z. Jin]
439. Ajinomoto Co., Inc., Pharmaceutical Research Institute, Kawasaki, Japan [Dr. M. Shoji, November 5, 2007].
440. Mitsubishi Chemical Group, Science and Technology Center, Yokohama, Japan [Dr. M. Takai, November 6, 2007].
441. Central Glass Co., Chemical Research Laboratory, Kawagoe, Japan [Dr. Y. Takahara, November 7, 2007]
442. The University of Tokyo, Graduate School of Pharmaceutical Sciences, Hongo, Tokyo, Japan [Prof. M. Inoue, November 8, 2007]
443. Schering-Plough Pharmaceutical Research Institute, Cambridge, MA [December 13, 2007, Dr. C. Dai]
444. City University of New York, Hunter College, NYC, NY [March 28, 2008, Prof. W. Herding]
445. Swiss Federal Institute of Technology, Lausanne (EPFL), Institute of Chemical Sciences and Egineering, Lausanne, Switzerland [May 27, 2008, Prof. K. Gademann]
446. F. Hoffmann-La Roche, AG, Pharma Research, Basel, Switzerland [May 30, 2008, Dr. H. P. Maerki, Dr. T. Woltering]
447. Université Pierre et Marie Curie (Paris VI), Institut de Chimie Moléculaire, Paris, France [June 2, 2008, Prof. L. Fensterbank, Prof. M. Maracria]
448. Université de Cergy-Pontoise, Laboratoire "Synthèse Organique Sélective et Chimie Organométallique", Cergy-Pontoise, France [June 3, 2008, Prof. T. Brigaurd]
449. Sanofi-Aventis, Chemical and Analytical Sciences, Vitry-sur-Seine, France [June 5, 2008, Dr. A. Commerçon]
450. Sundia Pharamceuticals, Inc., Shanghai, China [June 24, 2008, Dr. J. Zhu]
451. University of Wisconsin Milwaukee, Milwaukee, WI [Oct. 16-17, 2008, Prof. J. Cook]
452. Central Glass Co., Chemical Research Center, Kawagoe, Japan [Oct. 27, 2008, Dr. N. Takada, Dr. Y. Hibino]
453. RIKEN (The Institute of Physical and Chemical Research), Wako, Saitama, Japan [Oct. 28, 2008, Dr. M. Sodeoka]
454. The University of Tokyo, School of Engineering, Hongo, Tokyo, Japan [Oct. 29, 2008, Prof. M. Fujita]
455. Mitsubishi Chemical Group, Science and Technology Center, Yokohama, Japan [Oct. 30, 2008, Dr. M. Takai].
456. Ajinomoto Co., Inc., Pharmaceutical Research Institute, Kawasaki, Japan [Nov. 5, 2008, Dr. M. Shoji].
457. Kitasato Institute, Shirogane, Tokyo, Japan [Nov. 14, 2008, Prof. S. Omura].
458. Texas Tech University, Lubbock, TX [Feb. 24-25, 2009, Prof. G. Lee].
459. Genentech, South San Francisco, CA [April 8, 2009, Dr. F. Cohen]
460. National Cancer Institute-Frederic, Frederic-SAIC, Inc., Bethesda, MD [May 27, 2009, Dr. S. Malhotra, Dr. A. Pepe]
461. Nagoya Institute of Technology, Nagoya, Japan [Nov. 10, 2009, Prof. N. Shibata]
462. Ajinomoto Co., Inc., Pharmaceutical Research Institute, Kawasaki, Japan [Nov. 11, 2009, Dr. E. Nakanishi]
463. Chugai Pharmaceuticals Kamakura Research Center, Kamakura, Japan [Nov. 12, 2009, Dr. N. Shimma]
464. The University of Tokyo, Graduate School of Chemistry, Hongo, Tokyo, Japan [Nov. 14, 2009, Prof. E. Nakamura]
465. The Tosoh Organic Synthesis Seminar, Odaiba, Tokyo, Japan [April 22, 2010, Dr. K. Kato]
466. Ajinomoto Pharmaceuticala Co. Ltd., Pharmaceutical Research Laboratory, Kawasaki, Japan [Nov. 4, 2010, Dr. K. Sakurai, Dr. T. Tsuji]
467. Kitasato Institute and Kitasato University, Sirogane, Tokyo, Japan [Nov. 5, 2010, Prof. T. Sunazuka, Prof. S. Omura]
468. Shonan High School, Fujisawa, Japan [Nov. 6, 2010, Mr. M. Kato, Mr. A. Komuro]
469. Central Glass KK, Chemical Research Center, Kawagoe, Japan [Nov. 8, 2010, Dr. Hibino]
470. The University of Tokyo, Graduate School of Pharmaceutical Science, Hongo, Tokyo, Japan [Nov. 9, 2010, Prof. T. Fukuyama]
471. Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences, Baltimore, MD [March 2, 2011, Prof. J. Liu]
472. Colorado State University, Department of Microbiology, Immunology and Pathology, Fort Collins, CO [June 27, 2011] (scheduled)
In addition to these invited lectures, he and his laboratory members regularly present papers at the American Chemical Society's National Meetings, ACS Winter Fluorine Conference, American Association for Cancer Research (AACR) Annual Meeting.
